Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $7.40

Shares of Immunic, Inc. (NASDAQ:IMUX) have received an average recommendation of “Moderate Buy” from the eight research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $7.40.

A number of research analysts have recently commented on the company. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a research report on Thursday, October 16th. HC Wainwright dropped their price objective on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 14th. D. Boral Capital cut their target price on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, October 8th. Finally, Roth Capital began coverage on shares of Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 price target on the stock.

Immunic Stock Down 3.6%

Shares of IMUX stock opened at $0.69 on Tuesday. The firm has a market cap of $82.70 million, a P/E ratio of -0.73 and a beta of 1.53. The company has a 50 day moving average of $0.82 and a 200-day moving average of $0.85. Immunic has a 12-month low of $0.56 and a 12-month high of $1.42.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05. As a group, equities analysts expect that Immunic will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Immunic

Large investors have recently made changes to their positions in the stock. Focus Partners Wealth boosted its stake in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after purchasing an additional 415,104 shares during the period. Aberdeen Group plc lifted its holdings in shares of Immunic by 678.1% in the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after buying an additional 7,184,457 shares in the last quarter. 683 Capital Management LLC lifted its holdings in shares of Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after buying an additional 200,000 shares in the last quarter. Millennium Management LLC boosted its position in shares of Immunic by 414.5% in the third quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock valued at $468,000 after acquiring an additional 427,361 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Immunic during the third quarter valued at approximately $170,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.